Thomas DiRaimondo - 02 Jan 2026 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role: Chief Scientific Officer
Signature: /s/ James Pennington, Attorney-in-Fact
Issuer symbol: JANX
Transactions as of: 02 Jan 2026
Net transactions value: -$34,394
Form type: 4
Filing time: 02 Jan 2026, 21:00:15 UTC
Previous filing: 03 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
DiRaimondo Thomas	Chief Scientific Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO	/s/ James Pennington, Attorney-in-Fact	02 Jan 2026	0002005618

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JANX	Common Stock	Sale	$34,394	-2,505	-2%	$13.73	124,425	02 Jan 2026	Direct	F1, F2
transaction	JANX	Common Stock	Award	$0	+31,400	+25%	$0.000000	155,825	02 Jan 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JANX	Stock option (right to buy)	Award	$0	+109,900		$0.000000	109,900	02 Jan 2026	Common Stock	109,900	$13.65	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2	Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024.
F3	Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F4	25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.